Literature DB >> 25986475

Serum C-reactive protein and overall survival of patients with osteosarcoma.

Xiaochuan Li1, Feng Tian, Fei Wang, Yanfeng Li.   

Abstract

Increased level of serum C-reactive protein (CRP) has been identified as an important prognostic factor in several types of cancers. However, the prognostic significance of serum CRP levels in patients with osteosarcoma was still unclear. A retrospective cohort study of 85 patients was performed to assess the prognostic significance of serum CRP level in osteosarcoma. Both log-rank test and multivariable analysis by Cox regression model were used to assess the impact of serum CRP levels on the overall survival in patients with osteosarcoma. Among those 85 patients, 28 (32.9 %) had high serum CRP level (>1 mg/dL), while the other 57 (67.1 %) patients had normal serum CRP level (≤ 1 mg/dL). There was no obvious difference in the baseline characteristics between high CRP group and normal CRP group. Kaplan-Meier product-limit method showed that patients with high serum CRP levels had significantly poorer overall survival than those patients with normal serum CRP levels (log-rank test P = 0.0008). Multivariable analysis by Cox regression model further showed that high serum CRP level was an independent predictor of poor overall survival (hazard ratio [HR] = 2.39; 95 % confidence interval [95 % CI] 1.22-4.67, P = 0.01). Thus, serum CRP level has an important prognostic significance in patients with osteosarcoma, and high CRP level is associated with worse overall survival.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986475     DOI: 10.1007/s13277-015-3240-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  In brief: classifications in brief: enneking classification: benign and malignant tumors of the musculoskeletal system.

Authors:  Muhammad Umar Jawad; Sean P Scully
Journal:  Clin Orthop Relat Res       Date:  2010-07       Impact factor: 4.176

Review 2.  Palliative therapy for osteosarcoma.

Authors:  Costantino Errani; Alessandra Longhi; Giuseppe Rossi; Eugenio Rimondi; Alessio Biazzo; Angelo Toscano; Nikolin Alì; Pietro Ruggieri; Marco Alberghini; Piero Picci; Gaetano Bacci; Mario Mercuri
Journal:  Expert Rev Anticancer Ther       Date:  2011-02       Impact factor: 4.512

3.  Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.

Authors:  David C Turner; Fariba Navid; Najat C Daw; Shenghua Mao; Jianrong Wu; Victor M Santana; Michael Neel; Bhaskar Rao; Jennifer Reikes Willert; David M Loeb; K Elaine Harstead; Stacy L Throm; Burgess B Freeman; Clinton F Stewart
Journal:  Clin Cancer Res       Date:  2014-03-17       Impact factor: 12.531

Review 4.  Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?

Authors:  Jakob K Anninga; Hans Gelderblom; Marta Fiocco; Judith R Kroep; Antoni H M Taminiau; Pancras C W Hogendoorn; R Maarten Egeler
Journal:  Eur J Cancer       Date:  2011-06-22       Impact factor: 9.162

Review 5.  C-reactive protein and the biology of disease.

Authors:  Waliza Ansar; Shyamasree Ghosh
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

6.  Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study.

Authors:  Adriana Villaseñor; Shirley W Flatt; Catherine Marinac; Loki Natarajan; John P Pierce; Ruth E Patterson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-12       Impact factor: 4.254

7.  Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma.

Authors:  Kjetil Berner; Tom Børge Johannesen; Aasmund Berner; Hans Kristian Haugland; Bodil Bjerkehagen; Per J Bøhler; Øyvind S Bruland
Journal:  Acta Oncol       Date:  2014-06-24       Impact factor: 4.089

Review 8.  C-reactive protein: clinical and epidemiological perspectives.

Authors:  Juan Salazar; María Sofía Martínez; Mervin Chávez; Alexandra Toledo; Roberto Añez; Yaquelín Torres; Vanessa Apruzzese; Carlos Silva; Joselyn Rojas; Valmore Bermúdez
Journal:  Cardiol Res Pract       Date:  2014-02-06       Impact factor: 1.866

9.  Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma.

Authors:  Ola H Nada; Naglaa S Ahmed; Hoda H Abou Gabal
Journal:  Diagn Pathol       Date:  2014-03-25       Impact factor: 2.644

10.  MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma.

Authors:  Shi-hong Xu; Yong-liang Yang; Shu-mei Han; Zong-hui Wu
Journal:  World J Surg Oncol       Date:  2014-06-27       Impact factor: 2.754

View more
  10 in total

1.  C-reactive protein and tumour diagnosis predict survival in patients treated surgically for long bone metastases.

Authors:  Costantino Errani; Monica Cosentino; Giovanni Ciani; Lorenzo Ferra; Patricio A Alfaro; Barbara Bordini; Davide M Donati
Journal:  Int Orthop       Date:  2021-01-04       Impact factor: 3.075

2.  Prognostic value of inflammation-based scores in patients with osteosarcoma.

Authors:  Bangjian Liu; Yujing Huang; Yuanjue Sun; Jianjun Zhang; Yang Yao; Zan Shen; Dongxi Xiang; Aina He
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

3.  Prognostic value of the C-reactive protein to albumin ratio: a novel inflammation-based prognostic indicator in osteosarcoma.

Authors:  Yong-Jiang Li; Kai Yao; Min-Xun Lu; Wen-Biao Zhang; Cong Xiao; Chong-Qi Tu
Journal:  Onco Targets Ther       Date:  2017-11-02       Impact factor: 4.147

4.  Elevated serum C-reactive protein level predicts a poor prognosis for recurrent gastric cancer.

Authors:  Fanming Kong; Fangfang Gao; Jun Chen; Rongxiu Zheng; Honggen Liu; Xiaojiang Li; Peiying Yang; Geli Liu; Yingjie Jia
Journal:  Oncotarget       Date:  2016-08-23

5.  Prognostic value of C-reactive protein levels in patients with bone neoplasms: A meta-analysis.

Authors:  Wenyi Li; Xujun Luo; Zhongyue Liu; Yanqiao Chen; Zhihong Li
Journal:  PLoS One       Date:  2018-04-18       Impact factor: 3.240

6.  On detection of periodicity in C-reactive protein (CRP) levels.

Authors:  Mohsen Dorraki; Anahita Fouladzadeh; Stephen J Salamon; Andrew Allison; Brendon J Coventry; Derek Abbott
Journal:  Sci Rep       Date:  2018-08-10       Impact factor: 4.379

7.  The value of C-reactive protein as an independent prognostic indicator for disease-specific survival in patients with soft tissue sarcoma: A meta-analysis.

Authors:  Xiaolin Wang; Song Liu; Xiaoli Zhao; Erhu Fang; Xiang Zhao
Journal:  PLoS One       Date:  2019-07-01       Impact factor: 3.240

8.  Prognostic Value of Pretreated Blood Inflammatory Markers in Patients with Bone Sarcoma: A Meta-Analysis.

Authors:  Min Jiang; Shaowei Ma; Zhongyan Hua; Zhiying Zhao; Song Gao
Journal:  Dis Markers       Date:  2021-04-08       Impact factor: 3.434

9.  Exploration and Validation of a Novel Inflammatory Response-Associated Gene Signature to Predict Osteosarcoma Prognosis and Immune Infiltration.

Authors:  Yucheng Fu; Guoyu He; Zhuochao Liu; Jun Wang; Zhusheng Zhang; Qiyuan Bao; Junxiang Wen; Zhijian Jin; Weibin Zhang
Journal:  J Inflamm Res       Date:  2021-12-09

10.  Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis.

Authors:  Xiaotong Song; Hao Zhang; Fanxing Yin; Panpan Guo; Xiaocheng Yang; Jinzhu Liu; Yanshuo Han; Zhaozhou Ren
Journal:  Mediators Inflamm       Date:  2021-10-21       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.